Results 61 to 70 of about 3,298 (171)

Unveiling Antimalarial Drug Resistance: The Role of CRISPR‐Cas Technologies in Malaria Research

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Background Malaria, caused by Plasmodium parasites, remains a global health burden, with drug resistance threatening control efforts. CRISPR‐Cas technologies, particularly CRISPR‐Cas9, have transformed malaria research by enabling precise genetic manipulations to study antimalarial resistance mechanisms, develop novel therapeutics and enhance ...
Reuben Samson Dangana, Israel Ehizuelen Ebhohimen, Moses Okpeku, Jess Vergis   +3 more
wiley   +1 more source

Heterologous Expression and ATPase Activity of Mutant versus Wild Type PfMDR1 Protein^†

, 2016
Mutation of the P. falciparum chloroquine resistance transporter (PfCRT) causes resistance to chloroquine (CQ) and other antimalarial drugs. Mutation and/or overexpression of one of the multidrug resistance protein homologues found in this malarial ...
Linda E. Amoah (2491204), Jacqueline K. Lekostaj (2417041), Paul D. Roepe (484901)   +2 more
core   +1 more source

Mutations in Pfcrt and Pfmdr1.

, 2019
Mutations in Pfcrt and Pfmdr1.
Inke Lubis (6475796), Xiaodong Sun (166163), Wang Jiazhi (6475799), Susana Campino (56411), Colin J. Sutherland (257150), Taane G. Clark (106263), Jun Feng (116162), Lin-hua Tang (6475802), David C. Warhurst (250276), Ana Rita Gomes (220735), Khalid B. Beshir (816307), Fang Huang (154302), Yan He (116705), Ernest Diez Benavente (3711490)   +13 more
core   +1 more source

Image1_Plasmodium falciparum Drug Resistance Genes pfmdr1 and pfcrt In Vivo Co-Expression During Artemether-Lumefantrine Therapy.jpeg

, 2022
Background: Artemisinin-based combination therapies (ACTs) are the global mainstay treatment of uncomplicated Plasmodium falciparum infections. PfMDR1 and PfCRT are two transmembrane transporters, associated with sensitivity to several antimalarials ...
A. Björkman (6249143), A. Mårtensson (6249191), S. D. Otienoburu (12611293), M. Silva (7447316), J. P. Gil (12611299), M. Malmberg (12611290), B. Ngasala (12611296), M. I. Veiga (12611302)   +7 more
core   +1 more source

Sequence analysis of pfcrt and pfmdr1 genes and its association with chloroquine resistance in Southeast Indian Plasmodium falciparum isolates

Genomics Data, 2016
Background: Due to the widespread resistance of Plasmodium falciparum to chloroquine drug, artemisinin-based combination therapy (ACT) has been recommended as the first-line treatment. This study aims to evaluate the extent of chloroquine resistance in P.
Hiasindh Ashmi Antony, Sindhusuta Das, Subhash Chandra Parija, Sanghamitra Padhi   +3 more
doaj   +1 more source

Experimental Evolution of Reduced Susceptibility to Artemether–Lumefantrine in Plasmodium berghei Following Serial Drug Pressure

Journal of Parasitology Research, Volume 2026, Issue 1, 2026.
Malaria remains a major global health problem, with uneven progress and the greatest disease burden clustered in sub‐Saharan Africa. Antimalarial drug resistance continues to undermine malaria control efforts, with widespread resistance reported in Plasmodium falciparum, including reduced susceptibility to artemisinin‐based combination therapies (ACTs).
Stephen Mwangi Njoroge, Shadrack Kanyonji Kimani, Teresia Wambui Ngonjo, Maureen Stella Olunga, Julius Seng′ete Wambua, Milka Wambui Waithera, Hamida Yahaya Wawa, James Ng′ang′a Waweru, Satabdi Datta Choudhury   +8 more
wiley   +1 more source

Ein neuer Malariawirkstoff hemmt die Proteinsynthese von Plasmodium falciparum

Angewandte Chemie, Volume 137, Issue 49, December 1, 2025.
Die Verbindung 31 stellt einen vielversprechenden Ansatz für die Entwicklung eines Malariawirkstoffs mit einem starken Wirkungsprofil dar (PfNF54 IC50 ± s.d. = 3,9 ± 0,4 nM). Sie hat einen neuartigen Wirkmechanismus, indem sie an zytosolische Ribosomen‐Untereinheiten bindet und dadurch die Proteinsynthese im Parasiten hemmt.
Patricia Bravo, Eleonora Diamanti, Mostafa M. Hamed, Lorenzo Bizzarri, Natalie Wiedemar, Armin Passecker, Nicolas M. B. Brancucci, Anna Albisetti, Christin Gumpp, Boris Illarionov, Markus Fischer, Matthias Witschel, Tobias Schehl, Hannes Hahne, Pascal Mäser, Matthias Rottmann, Anna K. H. Hirsch   +16 more
wiley   +1 more source

Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya

International Journal for Parasitology: Drugs and Drug Resistance, 2014
Molecular surveillance of drug resistance markers through time provides crucial information on genomic adaptations, especially in parasite populations exposed to changing drug pressures.
John Okombo, Alice W. Kamau, Kevin Marsh, Colin J. Sutherland, Lynette Isabella Ochola-Oyier   +4 more
doaj   +1 more source

Molecular analysis demonstrates high prevalence of chloroquine resistance but no evidence of artemisinin resistance in Plasmodium falciparum in the Chittagong Hill Tracts of Bangladesh

Malaria Journal, 2017
Background Artemisinin resistance is present in the Greater Mekong region and poses a significant threat for current anti-malarial treatment guidelines in Bangladesh.
Mohammad Shafiul Alam, Benedikt Ley, Maisha Khair Nima, Fatema Tuj Johora, Mohammad Enayet Hossain, Kamala Thriemer, Sarah Auburn, Jutta Marfurt, Ric N. Price, Wasif A. Khan   +9 more
doaj   +1 more source

Decreased prevalence of the Plasmodium falciparum Pfcrt K76T and Pfmdr1 and N86Y mutations post-chloroquine treatment withdrawal in Katete District, Eastern Zambia

Malaria Journal, 2021
Background In 2002, Zambia withdrew chloroquine as first-line treatment for Plasmodium falciparum malaria due to increased treatment failure and worldwide spread of chloroquine resistance.
Mwenda C. Mulenga, Lungowe Sitali, Ilinca I. Ciubotariu, Moonga B. Hawela, Busiku Hamainza, James Chipeta, Sungano Mharakurwa   +6 more
doaj   +1 more source